Medpace Holdings, Inc. (MEDP) Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
Medpace Holdings, Inc. NASDAQ:MEDP Healthcare · Medical - Diagnostics & Research
AH Close $669.20 +0.00% vs close
AH Close $669.20 +0.00% vs close
All Press Release SEC Filings News
Press Release ● Major ⚠ 1
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year-over-year, with net new business awards of $873.4 million, up 10.6%.
GAAP net income rose to $137.5 million, or $4.84 per diluted share (vs. $3.86 a year ago), with net income margin expanding to 19.2% from 16.8%, and EBITDA grew 16.0% to $172.1 million at a 24.0% margin.
Backlog reached $3.17 billion, up 5.6% YoY, and the company generated $216.6 million in operating cash flow during the quarter, ending with $705.3 million in cash.
The board terminated the prior buyback authorization ($527.0 million remaining) and approved a new $1.0 billion repurchase program through December 31, 2028; FY2026 guidance was set at $2.835-$2.855 billion revenue and $17.97-$18.32 diluted EPS.
• 4d ago AI analysis › SEC Filing ⚠ 3
MEDP: SCHEDULE 13D/A · ownership disclosure
Medpace Holdings founder and controlling shareholder August J. Troendle filed Amendment No. 24 to his Schedule 13D, disclosing continued open-market sales of common stock between August 10 and September 25, 2026, executed via limit orders at prices mostly between $600 and $637 per share.
Following these sales, Troendle beneficially owns 5,396,508 shares, or 19.1% of the class, while Medpace Investors, LLC holds shared voting and dispositive power over 4,733,019 shares (16.8%).
This is the 24th amendment to the original 2016 Schedule 13D, indicating an ongoing, programmatic selling cadence; continued large insider supply overhang may weigh on MEDP shares even as sales occur at historically elevated price levels.
SEC SCHEDULE 13D/A • 26d ago AI analysis › Press Release
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Medpace Holdings will report third quarter 2026 financial results after the market close on Wednesday, October 21, 2026.
A conference call to discuss the results will be held the following morning, October 22, at 9:00 a.m. ET, with registration required for telephone participants and a webcast available at investor.medpace.com.
Medpace is a Cincinnati-based full-service clinical CRO employing approximately 6,500 people across 46 countries as of June 30, 2026.
• 1mo ago AI analysis › News
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
zacks.com • 1mo ago News
CON vs. MEDP: Which Stock Is the Better Value Option?
zacks.com • 1mo ago News
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
zacks.com • 1mo ago News
Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
investors.com • 1mo ago News
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
zacks.com • 1mo ago News
What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock
fool.com • 1mo ago Press Release
Lifshitz Law PLLC Announces Investigations of United Homes Group, Inc. (NASDAQ: UHG), Upstart Holdings, Inc. (NASDAQ: UPST), Medpace Holdings, Inc. (NASDAQ: MEDP), and Gossamer Bio, Inc. (NASDAQ: GOSS)
Lifshitz Law PLLC announced an investigation into Gossamer Bio regarding possible securities law violations related to the design of its Phase 3 PROSERA study.
The firm alleges the company concealed material adverse facts, specifically the failure to adequately control for placebo response at Latin American testing sites.
This is a routine solicitation encouraging GOSS investors to contact the law firm to discuss their rights.
• 2mo ago AI analysis › News
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
zacks.com • 2mo ago News
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
zacks.com • 2mo ago News
Medpace (NASDAQ:MEDP) CEO Sells $6,836,989.98 in Stock
defenseworld.net • 2mo ago News
CON or MEDP: Which Is the Better Value Stock Right Now?
zacks.com • 2mo ago News
Here's Why Medpace (MEDP) is a Strong Growth Stock
zacks.com • 2mo ago News
Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com • 2mo ago News
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
zacks.com • 2mo ago News
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
zacks.com • 2mo ago News
Why Medpace (MEDP) is a Top Momentum Stock for the Long-Term
zacks.com • 2mo ago News
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
zacks.com • 2mo ago News
Medpace: Cancellations Are Normalizing
seekingalpha.com • 3mo ago News
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
zacks.com • 3mo ago News
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
benzinga.com • 3mo ago News
Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earnings
seekingalpha.com • 3mo ago News
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
seekingalpha.com • 3mo ago News
Medpace Q2 Earnings Call Highlights
marketbeat.com • 3mo ago News
Medpace (MEDP) Beats Q2 Earnings and Revenue Estimates
zacks.com • 3mo ago News
Medpace Notches A Big Bookings Beat, And Reverses Its First-Quarter Malaise
investors.com • 3mo ago Press Release ● Major
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
Medpace delivered Q2 revenue of $707.3 million, up 17.2% year-over-year, with net income margin expanding to 17.2% from 15.0%.
Net new business awards jumped 28.2% to $795.7 million, resulting in a 1.13x book-to-bill ratio and backlog growth of 4.9% to $3.01 billion.
The company raised 2026 revenue guidance to $2.805 billion-$2.885 billion and repurchased $294.7 million of shares during the quarter.
• 3mo ago AI analysis › News
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
zacks.com • 3mo ago News
CON vs. MEDP: Which Stock Is the Better Value Option?
zacks.com • 3mo ago News
Why Medpace (MEDP) Dipped More Than Broader Market Today
zacks.com • 3mo ago News
A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF Value $503.39 vs Price $546.29
gurufocus.com • 3mo ago News
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
zacks.com • 3mo ago News
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
zacks.com • 3mo ago News
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
zacks.com • 3mo ago News
CON or MEDP: Which Is the Better Value Stock Right Now?
zacks.com • 3mo ago News
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
zacks.com • 3mo ago News
Is It Too Late to Buy Medpace Holdings Inc (MEDP) After 3.9% Rally? GF Value Says Undervalued
gurufocus.com • 4mo ago News
Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights
zacks.com • 4mo ago Press Release
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026.
The company will host a conference call to discuss these results on Thursday, July 23, 2026 at 9:00 a.m. ET, requiring advance registration for participants.
A supplemental slide presentation will be made available on the Investors section of Medpace's website prior to the start of the call.
• 4mo ago AI analysis › News
CON vs. MEDP: Which Stock Is the Better Value Option?
zacks.com • 4mo ago News
Why the Market Dipped But Medpace (MEDP) Gained Today
zacks.com • 4mo ago Press Release ● Major
Safirstein Law LLC Announces That A Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP)
globenewswire.com • 4mo ago SEC Filing
MEDP: 8-K · leadership change
Medpace Holdings, Inc. appointed Brad W. Hansman as Executive Vice President, Operations, effective June 1, 2026. He will serve as principal operating officer alongside existing EVP Susan E. Burwig.
Hansman has been with the company since 2011, previously holding leadership roles in operations including study start-up and regulatory affairs. His appointment reflects internal succession planning rather than an external hire.
In connection with the promotion, Hansman will receive an annual base salary of $492,250 and participate in the company’s short-term and long-term incentive plans.
SEC 8-K • 4mo ago AI analysis › News
Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade
zacks.com • 4mo ago Recent SEC filings with analysis 
